Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Back in at $5.50, seems to have been a bad move?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(325)
•••
Comment by Actuarialon Feb 09, 2021 12:53pm
109 Views
Post# 32514044

RE:RE:RE:RE:RE:Back in at $5.50, seems to have been a bad move?

RE:RE:RE:RE:RE:Back in at $5.50, seems to have been a bad move?Go back to your orignal post - full of shiits to bash the company and undermine Dan. Who is the worm enjoy distributing insults? Go back to my original post - I only ask a decent question - what's wrong with you when you blame Dan not to release the ringing of the bell and also deny the impact of the ringing of the bell. Your brain is full of contradictive mess. Don't you know it yourself?
Kazam1961 wrote:
Actuarial....For those who enjoy distributing insults, the internet is a perfect environment, one that can offer a shield of anonymity and an absence of consequences. The larger question is whether the frequency of ill-motivated personal attacks will ride the wave of increasing narcissism or succumb to social controls?   


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities